These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33603754)

  • 21. [Prognostic Value of CD14
    Wu CX; Qiang M; Hao JQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Jun; 27(3):816-819. PubMed ID: 31204937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function.
    Gielen PR; Schulte BM; Kers-Rebel ED; Verrijp K; Bossman SA; Ter Laan M; Wesseling P; Adema GJ
    Neuro Oncol; 2016 Sep; 18(9):1253-64. PubMed ID: 27006175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
    Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
    Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mass cytometry defines distinct immune profile in germinal center B-cell lymphomas.
    Roussel M; Lhomme F; Roe CE; Bartkowiak T; Gravelle P; Laurent C; Fest T; Irish JM
    Cancer Immunol Immunother; 2020 Mar; 69(3):407-420. PubMed ID: 31919622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasticity of myeloid-derived suppressor cells in cancer.
    Tcyganov E; Mastio J; Chen E; Gabrilovich DI
    Curr Opin Immunol; 2018 Apr; 51():76-82. PubMed ID: 29547768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic Significance of Monocytes and Monocytic Myeloid-Derived Suppressor Cells in Diffuse Large B-Cell Lymphoma Treated with R-CHOP.
    Wu C; Wu X; Liu X; Yang P; Xu J; Chai Y; Guo Q; Wang Z; Zhang L
    Cell Physiol Biochem; 2016; 39(2):521-30. PubMed ID: 27383764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. slan
    Vermi W; Micheletti A; Finotti G; Tecchio C; Calzetti F; Costa S; Bugatti M; Calza S; Agostinelli C; Pileri S; Balzarini P; Tucci A; Rossi G; Furlani L; Todeschini G; Zamò A; Facchetti F; Lorenzi L; Lonardi S; Cassatella MA
    Cancer Res; 2018 Jul; 78(13):3544-3559. PubMed ID: 29748373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatobiliary malignancies have distinct peripheral myeloid-derived suppressor cell signatures and tumor myeloid cell profiles.
    Bayik D; Lauko AJ; Roversi GA; Serbinowski E; Acevedo-Moreno LA; Lanigan C; Orujov M; Lo A; Alban TJ; Kim A; Silver DJ; Nagy LE; Brown JM; Allende DS; Aucejo FN; Lathia JD
    Sci Rep; 2020 Nov; 10(1):18848. PubMed ID: 33139767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High levels of Tim-3
    Zhong W; Liu X; Zhu Z; Li Q; Li K
    Int Immunopharmacol; 2021 Jul; 96():107662. PubMed ID: 33864956
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A super-SILAC based proteomics analysis of diffuse large B-cell lymphoma-NOS patient samples to identify new proteins that discriminate GCB and non-GCB lymphomas.
    van der Meeren LE; Kluiver J; Rutgers B; Alsagoor Y; Kluin PM; van den Berg A; Visser L
    PLoS One; 2019; 14(10):e0223260. PubMed ID: 31603917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor cell and immune cell profiles in primary human glioblastoma: Impact on patient outcome.
    González-Tablas Pimenta M; Otero Á; Arandia Guzman DA; Pascual-Argente D; Ruíz Martín L; Sousa-Casasnovas P; García-Martin A; Roa Montes de Oca JC; Villaseñor-Ledezma J; Torres Carretero L; Almeida M; Ortiz J; Nieto A; Orfao A; Tabernero MD
    Brain Pathol; 2021 Mar; 31(2):365-380. PubMed ID: 33314398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Importance of myeloid derived suppressor cells in cancer from a biomarker perspective.
    Kalathil SG; Thanavala Y
    Cell Immunol; 2021 Mar; 361():104280. PubMed ID: 33445053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating Monocytic Myeloid-Derived Suppressor Cells Are Elevated and Associated with Poor Prognosis in Acute Myeloid Leukemia.
    Wang H; Tao Q; Wang Z; Zhang Q; Xiao H; Zhou M; Dong Y; Zhai Z
    J Immunol Res; 2020; 2020():7363084. PubMed ID: 33415170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunophenotyping of Circulating Myeloid-Derived Suppressor Cells (MDSC) in the Peripheral Blood of Cancer Patients.
    Bruderek K; Schirrmann R; Brandau S
    Methods Mol Biol; 2021; 2236():1-7. PubMed ID: 33237535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutational, immune microenvironment, and clinicopathological profiles of diffuse large B-cell lymphoma and follicular lymphoma with BCL6 rearrangement.
    Carreras J; Ikoma H; Kikuti YY; Miyaoka M; Hiraiwa S; Tomita S; Kondo Y; Ito A; Nagase S; Miura H; Kawada H; Roncador G; Campo E; Hamoudi R; Nakamura N
    Virchows Arch; 2024 Apr; 484(4):657-676. PubMed ID: 38462571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of peripheral monocytic myeloid-derived suppressor cells and monocytes in patients newly diagnosed with diffuse large b-cell lymphoma.
    Wu C; Wu X; Zhang X; Chai Y; Guo Q; Li L; Yue L; Bai J; Wang Z; Zhang L
    Int J Clin Exp Med; 2015; 8(9):15173-81. PubMed ID: 26629001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lymphocyte-to-monocyte ratio is associated with prognosis of diffuse large B-cell lymphoma: correlation with CD163 positive M2 type tumor-associated macrophages, not PD-1 positive tumor-infiltrating lymphocytes.
    Wang J; Gao K; Lei W; Dong L; Xuan Q; Feng M; Wang J; Ye X; Jin T; Zhang Z; Zhang Q
    Oncotarget; 2017 Jan; 8(3):5414-5425. PubMed ID: 28036275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer-Associated Fibroblasts Promote Immunosuppression by Inducing ROS-Generating Monocytic MDSCs in Lung Squamous Cell Carcinoma.
    Xiang H; Ramil CP; Hai J; Zhang C; Wang H; Watkins AA; Afshar R; Georgiev P; Sze MA; Song XS; Curran PJ; Cheng M; Miller JR; Sun D; Loboda A; Jia Y; Moy LY; Chi A; Brandish PE
    Cancer Immunol Res; 2020 Apr; 8(4):436-450. PubMed ID: 32075803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathologic significance of tumor microenvironment CD11c, and FOXP3 expression in diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy.
    Lee S; Kim DH; Oh SY; Kim SY; Koh MS; Lee JH; Lee S; Kim SH; Kwak JY; Pak MG; Ju MH; Kim HJ; Jeong JS
    Korean J Intern Med; 2017 Mar; 32(2):335-344. PubMed ID: 26968188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma-New Therapeutic Targets.
    Mitteldorf C; Berisha A; Pfaltz MC; Broekaert SMC; Schön MP; Kerl K; Kempf W
    Am J Surg Pathol; 2017 Jul; 41(7):998-1004. PubMed ID: 28504999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.